Stem definition | Drug id | CAS RN |
---|---|---|
cardiac stimulants, amrinone derivatives | 1809 | 78415-72-2 |
Dose | Unit | Route |
---|---|---|
50 | mg | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 1 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 85 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 5.35 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 86 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.25 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 6.20 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.04 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.80 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 31, 1987 | FDA | SANOFI AVENTIS US |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Fear | 185.92 | 40.16 | 56 | 2151 | 16116 | 46667739 |
Renal injury | 172.32 | 40.16 | 47 | 2160 | 9494 | 46674361 |
Injury | 172.16 | 40.16 | 68 | 2139 | 43959 | 46639896 |
Renal failure | 162.21 | 40.16 | 87 | 2120 | 113507 | 46570348 |
Anhedonia | 159.47 | 40.16 | 45 | 2162 | 10290 | 46673565 |
Multiple organ dysfunction syndrome | 141.72 | 40.16 | 62 | 2145 | 51648 | 46632207 |
Unevaluable event | 138.44 | 40.16 | 59 | 2148 | 46116 | 46637739 |
Emotional distress | 132.53 | 40.16 | 51 | 2156 | 30656 | 46653199 |
Cardiogenic shock | 99.42 | 40.16 | 35 | 2172 | 16349 | 46667506 |
Stress | 80.36 | 40.16 | 42 | 2165 | 51509 | 46632346 |
Renal impairment | 68.54 | 40.16 | 43 | 2164 | 74329 | 46609526 |
Anxiety | 65.75 | 40.16 | 60 | 2147 | 181897 | 46501958 |
Hypotension | 41.76 | 40.16 | 53 | 2154 | 232536 | 46451319 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Fear | 247.14 | 37.34 | 74 | 2668 | 10751 | 29938985 |
Injury | 226.12 | 37.34 | 82 | 2660 | 21649 | 29928087 |
Renal injury | 203.54 | 37.34 | 65 | 2677 | 11664 | 29938072 |
Anhedonia | 203.06 | 37.34 | 60 | 2682 | 8309 | 29941427 |
Unevaluable event | 202.59 | 37.34 | 84 | 2658 | 31701 | 29918035 |
Emotional distress | 165.72 | 37.34 | 60 | 2682 | 15705 | 29934031 |
Renal failure | 144.58 | 37.34 | 108 | 2634 | 128858 | 29820878 |
Stress | 123.72 | 37.34 | 52 | 2690 | 20183 | 29929553 |
Anxiety | 106.57 | 37.34 | 78 | 2664 | 89793 | 29859943 |
Multiple organ dysfunction syndrome | 86.42 | 37.34 | 60 | 2682 | 63427 | 29886309 |
Pain | 78.13 | 37.34 | 87 | 2655 | 172554 | 29777182 |
Renal impairment | 73.43 | 37.34 | 61 | 2681 | 84123 | 29865613 |
Cardiogenic shock | 43.49 | 37.34 | 24 | 2718 | 16837 | 29932899 |
Cardiac failure | 39.18 | 37.34 | 43 | 2699 | 83375 | 29866361 |
Source | Code | Description |
---|---|---|
ATC | C01CE02 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Phosphodiesterase inhibitors |
FDA MoA | N0000175086 | Phosphodiesterase 3 Inhibitors |
FDA EPC | N0000175598 | Phosphodiesterase 3 Inhibitor |
MeSH PA | D002316 | Cardiotonic Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D006401 | Hematologic Agents |
MeSH PA | D058987 | Phosphodiesterase 3 Inhibitors |
MeSH PA | D010726 | Phosphodiesterase Inhibitors |
MeSH PA | D010975 | Platelet Aggregation Inhibitors |
MeSH PA | D020011 | Protective Agents |
MeSH PA | D014665 | Vasodilator Agents |
CHEBI has role | CHEBI:35620 | vasodilator |
CHEBI has role | CHEBI:38147 | cardiotonic drugs |
CHEBI has role | CHEBI:50427 | platelet aggregation inhibitors |
CHEBI has role | CHEBI:50568 | cyclic nucleotide phosphodiesterase inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Decompensated cardiac failure | indication | 195111005 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Conduction disorder of the heart | contraindication | 44808001 | |
Low blood pressure | contraindication | 45007003 | |
Pulmonic valve stenosis | contraindication | 56786000 | DOID:6420 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Idiopathic hypertrophic subaortic stenosis | contraindication | 360465008 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 6.97 | acidic |
pKa2 | 6.24 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Enzyme | INHIBITOR | IC50 | 6.36 | CHEMBL | CHEMBL | |||
cGMP-specific 3',5'-cyclic phosphodiesterase | Enzyme | IC50 | 6.13 | CHEMBL | |||||
cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Enzyme | IC50 | 6.55 | CHEMBL | |||||
Phosphodiesterase 4 | Enzyme | IC50 | 5.22 | CHEMBL | |||||
Phosphodiesterase 3 | Enzyme | Ki | 6.82 | CHEMBL | |||||
Cyclic nucleotide phosphodiesterase PDE3A | Enzyme | IC50 | 6.07 | CHEMBL | |||||
Cyclic AMP-specific phosphodiesterase SSPDE4A1A | Enzyme | IC50 | 4.89 | CHEMBL | |||||
cGMP-specific 3',5'-cyclic phosphodiesterase | Enzyme | IC50 | 5.30 | CHEMBL | |||||
Uncharacterized protein | Enzyme | IC50 | 6 | CHEMBL | |||||
cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Enzyme | Ki | 5.33 | CHEMBL |
ID | Source |
---|---|
4023601 | VUID |
N0000021606 | NUI |
D00417 | KEGG_DRUG |
100286-97-3 | SECONDARY_CAS_RN |
4020722 | VANDF |
4023601 | VANDF |
C1563869 | UMLSCUI |
CHEBI:50693 | CHEBI |
MIL | PDB_CHEM_ID |
CHEMBL189 | ChEMBL_ID |
CHEMBL1200977 | ChEMBL_ID |
D020105 | MESH_DESCRIPTOR_UI |
DB00235 | DRUGBANK_ID |
4197 | PUBCHEM_CID |
5225 | IUPHAR_LIGAND_ID |
5383 | INN_ID |
JU9YAX04C7 | UNII |
155120 | RXNORM |
43671 | MMSL |
5116 | MMSL |
6676 | MMSL |
d00302 | MMSL |
004083 | NDDF |
004084 | NDDF |
108480007 | SNOMEDCT_US |
108481006 | SNOMEDCT_US |
373441005 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Milrinone Lactate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9326 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 23 sections |
Milrinone Lactate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9373 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 19 sections |
Milrinone Lactate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9374 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 19 sections |
Milrinone Lactate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9708 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 25 sections |
Milrinone Lactate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9709 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 25 sections |
Milrinone Lactate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9710 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 25 sections |
Milrinone Lactate in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9718 | INJECTION, SOLUTION | 200 ug | INTRAVENOUS | ANDA | 21 sections |
Milrinone Lactate in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9719 | INJECTION, SOLUTION | 200 ug | INTRAVENOUS | ANDA | 21 sections |
Milrinone Lactate in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-6010 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 23 sections |
Milrinone Lactate in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-6011 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 23 sections |
MILRINONE LACTATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-0212 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 11 sections |
Milrinone Lactate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2776 | INJECTION, SOLUTION | 200 ug | INTRAVENOUS | ANDA | 25 sections |
Milrinone Lactate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6065 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 25 sections |
Milrinone Lactate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6067 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 25 sections |
Milrinone Lactate in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-313 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 23 sections |
Milrinone Lactate | Human Prescription Drug Label | 1 | 55150-287 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 21 sections |
Milrinone Lactate | Human Prescription Drug Label | 1 | 55150-288 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 21 sections |
Milrinone Lactate | Human Prescription Drug Label | 1 | 63323-617 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 11 sections |
Milrinone Lactate | Human Prescription Drug Label | 1 | 65145-120 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 18 sections |
Milrinone Lactate | Human Prescription Drug Label | 1 | 65145-121 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 18 sections |
Milrinone Lactate | Human Prescription Drug Label | 1 | 65145-122 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 18 sections |
Milrinone Lactate | Human Prescription Drug Label | 1 | 68083-318 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 22 sections |
Milrinone Lactate in Dextrose | Human Prescription Drug Label | 1 | 68083-410 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 19 sections |
Milrinone Lactate in Dextrose | Human Prescription Drug Label | 1 | 68083-411 | INJECTION, SOLUTION | 0.20 mg | INTRAVENOUS | ANDA | 19 sections |
Milrinone Lactate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-200 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 23 sections |